Results 101 to 110 of about 340 (164)

[Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer]. [PDF]

Rev Med Inst Mex Seguro Soc
Barboza-García YG, Ramírez-Balderrama L, Murguía-Pérez M, Hernández-González MA, Landeros-Navarro IY.   +4 more
europepmc   +1 more source

[Pattern of invasive growth of pituitary adenomas with positive hormonal immunohistochemistry]. [PDF]

Rev Med Inst Mex Seguro Soc
Bello-Lemus VH, Torres-Zapiain F, Murillo-Ortiz BO.   +2 more
europepmc   +1 more source

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). [PDF]

J Clin Oncol
Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teulé A, Custodio A, Tafuto S, La Casta A, Spada F, López C, Ibrahim T, Iranzo V, García-Alfonso P, González-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Álvarez G, Soldevilla B, Capdevila J.   +24 more
europepmc   +1 more source

[Solid Pseudopapillary Neoplasm of the Pancreas: Diagnosis and Surgical Management in a Young Patient]. [PDF]

Acta Gastroenterol Latinoam
García Alba EL, Chahdi Beltrame M, Ruíz NS, Cervantes G, Lenz Virreira ME, Mattera FJ, Quiñonez EG.   +6 more
europepmc   +1 more source

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). [PDF]

Clin Cancer Res
Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, Garcia-Carbonero R, Teulé A, Custodio A, Jimenez-Fonseca P, López C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, García-Álvarez A, Alonso-Gordoa T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E.   +19 more
europepmc   +1 more source

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

Endocr Rev, 2023
Garcia-Carbonero R, Anton-Pascual B, Modrego A, Del Carmen Riesco-Martinez M, Lens-Pardo A, Carretero-Puche C, Rubio-Cuesta B, Soldevilla B.   +7 more
europepmc   +1 more source

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. [PDF]

Nat Commun
Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, Álvarez-Escolá C, Carmona-Bayonas A, Ballester Navarro I, Iglesias L, Bover M, Garcia-Alvarez A, Lavernia J, Yayá Tur R, Ruiz S, Baste N, Lorenzo-Lorenzo I, Sanchez-Hernandez A, Sanz-Garcia E, Marquina G, Nuciforo P, Elguero B, Grande E, Alonso-Gordoa T.   +23 more
europepmc   +1 more source

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. [PDF]

ESMO Open
Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R, Klümpen HJ, Cremer B, Sevilla I, Eriksson B, Tabaksblat E, Metges JP, Reed NS, Schrader J, Navarro V, Valentí V, Hernando J, Colao AM, Vestermark L, Carnaghi C, Knigge UP, Jimenez-Fonseca P, Benavent M, de Vos-Geelen J, Venerito M, Von Werder A, Jann H, Rinke A, Smith D, Hörsch D, Starling N, Ruszniewski P, Baudin E, Caroli-Bosc FX, Manzano JL, Martín M, Scarpa A, Lawlor RT, Ragulan C, Ps H, Sadanandam A, Carmona-Bayonas A, Salazar R.   +41 more
europepmc   +1 more source

Pheochromocytoma/paraganglioma type 5 syndrome as a cause of secondary hypertension in a Colombian patient: case report [PDF]

Biomedica
Morales J, Arturo D, Folleco M.
europepmc   +1 more source

NON-FUNCTIONING SPORADIC PANCREATIC NEUROENDOCRINE TUMOR IS AN INDEPENDENT RISK FACTOR FOR RECURRENCE AFTER SURGICAL TREATMENT. [PDF]

Arq Bras Cir Dig
Figueira ERR, Montagnini AL, Okubo J, Fernandes AGV, Pereira MA, Ribeiro Junior U, Herman P, Jukemura J.   +7 more
europepmc   +1 more source